Granules India is currently trading at Rs. 91.60, up by 2.00 points or 2.23% from its previous closing of Rs. 89.60 on the BSE.
The scrip opened at Rs. 90.00 and has touched a high and low of Rs. 92.00 and Rs. 89.15 respectively. So far 24524 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 123.35 on 10-Sep-2018 and a 52 week low of Rs. 79.00 on 10-Dec-2018.
Last one week high and low of the scrip stood at Rs. 95.50 and Rs. 88.90 respectively. The current market cap of the company is Rs. 2328.91 crore.
The promoters holding in the company stood at 42.90%, while Institutions and Non-Institutions held 16.99% and 40.11% respectively.
Granules India’s wholly owned foreign subsidiary — Granules Pharmaceuticals, Inc. has received approval for the Abbreviated New Drug Application (ANDA) from US Food & Drug Administration (USFDA) for Amphetamine Sulfate Tablets USP 5 mg and 10 mg. It is bioequivalent to the reference listed drug product (RLD), Evekeo Tablets, 5 mg and 10 mg, of Arbor Pharmaceuticals, LLC.
Amphetamine Sulfate tablets is a central nervous system stimulant used to treat sleep disorder, increase attention, decrease impulsiveness and hyperactivity in patients with Attention Deficit Hyperactivity Disorder (ADHD).
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).